The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Having a Beer After SVR

Back to News Homepage

Next

EU Approves Drug That Is Up to 100% Effective Against Hep C

HCV Drug Update: Daklinza Gets Europe Approval

September 3, 2014

Print this page

Daklinza, a Bristol-Myers Squibb Inc. drug, was approved for the treatment of Hepatitis C in Japan and now in Europe as well.

Bristol-Myers Hepatitis C Treatment Gets Europe Approval

Daklinza Drug Combination Has Shown Strong Cure Rates, Company Says

By Michael Calia
AugustĀ  27, 2014

European regulators have approved a Bristol-Myers Squibb Inc. BMY +0.22% drug for use in hepatitis C combination treatments, the company said Wednesday.

The ruling by the European Commission allows for the drug, Daklinza, to be marketed in all of the European Union’s member states, Bristol said.

Continue reading this entire article:
http://online.wsj.com/articles/bristol-myers-hepatitis-c-treatment-gets-europe-approval-1409136824

No Comments - be the first!
Share
Share

Previous

Having a Beer After SVR

Back to News Homepage

Next

EU Approves Drug That Is Up to 100% Effective Against Hep C

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.